Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up (Blood Cancer Journal, (2025), 15, 1, (129), 10.1038/s41408-025-01329-2) Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage Blood Cancer Journal, 2026 Following the publication of this article, the authors noted the following sentence could be misinterpreted: 'In patients with ALK-sALCL, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5-70.2%)and 56.0%(39.3-69.7%) in the A + CHP and CHOP arms, respectively'.This sentence is in fact about patients with ALK-sALCL who achieved a complete response (CR), and while the sentence appears in the context of a paragraph discussing patients with a CR, the following correction has been made to avoid confusion: 'In patients with ALK-sALCL who achieved CR, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5-70.2%)and 56.0%(39.3-69.7%) in the A + CHP and CHOP arms, respectively'.Data showing 5-year PFS in patients with ALKdisease, regardless of response, appear in Figure 1.
Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy Pier Luigi Zinzani, Giulia Dell’Omo, Letizia Fusco, Ilaria Peduto, Carlotta Galeone, Federica Cavallo, Giuseppe Gritti Hematological Oncology, 2026 Compassionate Use Programs (CUP) offers patients with severe diseases, early access to promising new drugs outside of clinical trial and prior to marketing approval. Data arising from CUP provides valuable insights on treatment pathways. In the last few years, the treatment landscape for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) has rapidly evolved based on the approval of several novel therapies, resulting in changing treatment patterns which benefit from assessment of modern retrospective data. To address this, we retrospectively evaluated data of two large patient cohorts of r/r DLBCL within the polatuzumab vedotin and glofitamab Roche Global CUP opened in Italy [1], as was done in similar studies from other European countries [2, 3]. In fact, this analysis did not evaluate the effectiveness of the two products, that has been recently reported for polatuzumab vedotin [4]. The polatuzumab vedotin-rituximab +/− bendamustine CUP cohort included r/r DLBCL patients after at least 2 lines of treatment; with 208 patient requests received from 92 national centers between May 2019 and April 2020. The glofitamab CUP cohort included patients with r/r DLBCL, high-grade B-cell lymphoma (HGBCL) or primary mediastinal B cell lymphoma (PMBCL) after at least 3 lines of previous treatments; with 145 patient requests received from 59 national centers between March 2022 and April 2024. Cohort characteristics were compared using the Chi-square or Fisher's exact test for categorical data, and the Wilcoxon rank-sum test for continuous data. Clinical characteristics of the patient population are summarized in Table 1. Both cohorts showed a prevalence of males. The median age (minimum-maximum range) at diagnosis was higher in the polatuzumab vedotin-rituximab +/− bendamustine cohort (63 years; range: 24–84 years) compared to the glofitamab cohort (60 years; range: 17–82 years, p-value = 0.002). Similarly, the median age at CUP request was higher in the polatuzumab vedotin-rituximab +/− bendamustine (67 years; range: 25–85 years) than in the glofitamab cohort (62 years; range: 19–85 years, p-value < 0.001). The median duration from diagnosis to CUP request was comparable in the two cohorts (median 2 years, range 0–22). In the polatuzumab vedotin cohort, 78% patients were previously treated with 2 (49%) or 3 (29%) lines of treatment, whereas the glofitamab cohort had 79% of patients previously treated with 3 (34%) or 4 (45%) lines of treatment (p-value = 0.004). Total N = 353 Polatuzumab vedotin N = 208 Glofitamab N = 145 Treatment courses experienced by patients across the two cohorts are depicted in Figure 1. In the polatuzumab vedotin-rituximab +/− bendamustine cohort (Figure 1A), the most frequent frontline regimen was R-CHOP (66%), followed by R-CHOP like (e.g., R-COMP, R-COMP + rituximab, R-BENDA, etc; 23%) and by R-CHOP dose-dense chemotherapy (e.g., DA-EPOCH-R, MACOP-B, etc; 10%). The corresponding distribution in the glofitamab cohort (Figure 1B) was 59%, 17% and 24%, respectively. In both cohorts the use of R-CHOP dose-dense chemotherapy was more frequent in younger patients (median age: 51 years, range: 33–78 years in the polatuzumab vedotin-rituximab +/− bendamustine cohort; median age: 54 years, range: 17–72 years in the glofitamab cohort) as compared to R-CHOP standard-dose regimen (median age: 63 years, range: 24–83 years in the polatuzumab vedotin-rituximab +/− bendamustine cohort; median age: 59 years, range: 17–83 years in the glofitamab cohort). Sankey diagram reporting treatment flow of patients before entering polatuzumab vedotin (Panel A) and glofitamab (Panel B) compassionate use programs. In second line, in the polatuzumab vedotin-rituximab +/− bendamustine cohort, we observed that 63% of patients were treated with high dose chemotherapy and stem cell transplantation (SCT), at a median age of 61 years (range: 24–78 years), whereas in the glofitamab cohort the corresponding percentage was 75% and the median age was 57 years (range: 18–76 years). In both cohorts, the use of second-line chemo-free regimens was limited (< 10%) and was mainly reserved for older patients, with a median age of 73 years in both the polatuzumab vedotin-rituximab +/− bendamustine (range: 60–82 years) and glofitamab cohorts (range: 18–84 years). Third line treatment significantly differed in the two cohorts due to the different period observed that is, 2019–20 in the polatuzumab vedotin-rituximab +/− bendamustine and 2022–24 in the glofitamab cohort. In the polatuzumab vedotin-rituximab +/− bendamustine cohort, 28% of cases were treated with high dose chemotherapy and SCT, and 26% with chemo-free regimens, while in the glofitamab cohort 33% of patients were treated with polatuzumab vedotin, 28% with CAR-T therapy, and 15% each with high dose chemotherapy and SCT or chemo-free regimens. The two CUPs generated data to observe the treatment pathways of r/r DLBCL in Italy in two different time periods. A significant shift toward use of novel immunotherapies (primarily, polatuzumab vedotin and CAR-T), particularly after two lines of treatment, emerged in the descriptive analyses of the two cohorts. Earlier Italian data from the STRIDER study which evaluated first and second line therapy in DLBCL patients from 2010–2019 reported use of lenalidomide, platinum-based regimens, investigational drugs and other various regimens in third line of treatment [5], highlighting the urgency for widespread approval of novel treatments such as CAR-T cells and bispecific antibodies as second-line to improve r/r DLBCL patients outcomes. Moreover the commercial availability of CAR-T cell therapy (November 2019 Yescarta) and polatuzumab vedotin (January 2022) has been captured our observation (Sankey Diagram, Figure 1). Consistent with what was observed in the glofitamab cohort, recent data from the European transplant registry confirms that the use of high dose chemotherapy and SCT is progressively declining with the availability of new immunotherapies [6]. The current therapeutic landscape is also rapidly evolving, with second-line CAR-T therapy and first-line pola-R-CHP now established standards of care. Due to the temporal constraints of our cohorts and the requirement of ≥ 3 prior treatment lines for CUP eligibility, our dataset cannot yet reflect the impact of these recent advances on treatment sequencing, thus limiting the relevance of the observed sequencing in the current clinical practice. In conclusion, it provided insights into the evolving treatment pathways in Italy across two distinct time periods, showing the shift toward earlier use of novel immunotherapies. This approach may serve as a valuable complement to traditional data-generation methods, enhancing the understanding of treatment sequencing in patients with r/r DLBCL within a rapidly evolving therapeutic landscape. The authors gratefully acknowledge Pier Luigi Zinzani, Federica Cavallo and Giuseppe Gritti for their valuable contribution of expertise and time towards the interpretation of the results and the critical review of this manuscript without financial compensation. The retrospective analysis was sponsored by Roche SpA. Pier Luigi Zinzani: Consultant for MSD, Takeda, Recordati, Novartis, Speakers bureau for Sobi, Kite-Gilead, Janssen, BMS, MSD, AstraZeneca, Takeda, Roche, Recordati, Kyowa Kirin, Novartis, Incyte, Beigene, Advisory Board for Sobi, Kite-Gilead, Janssen, BMS, MSD, AstraZeneca, Takeda, Roche, Recordati, Kyowa Kirin, Novartis, ADC Therap., Incyte, Beigene; Giulia Dell’Omo, Letizia Fusco and Ilaria Peduto are employees of Roche SpA; Carlotta Galeone performed statistical analysis for Roche; Federica Cavallo: Advisory Board for Roche, Speakers fee and Research grant from Roche; Giuseppe Gritti: Advisory Board for Abbvie, Roche, Takeda, Kite-Gilead, Genmab, Speaker's bureau for Takeda, Ideogen, Genmab, Support for attending meetings from Kite-Gilead, Janssen, Research support from Ideogen. The datasets generated and/or analyzed are available from the corresponding author on reasonable request. For up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related documents, see here: go.roche.com/data_sharing.
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy Daniela Estefania Banegas, Isacco Ferrarini, Andrea Bernardelli, Alessia Moioli, Vittorio Ruggero Zilioli, Luca Nassi, Chiara Rusconi, Beatrice Casadei, Cinzia Pellegrini, Guido Gini, Giuseppe Gritti, Giulia Daghia, Elsa Pennese, Luigi Petrucci, Simone Ferrero, Sonya De Lorenzo, Sara Veronica Usai, Ausilia Gorgone, Massimo Gentile, Alessia Castellino, Anna Vanazzi, Luigi Curreli, Lucia Morello, Monica Tani, Daniela Renzi, Brunella Mola, Alberto Fabbri, Alfredo Molteni, Roberta Sciarra, Pier Luigi Zinzani, Carlo Visco Leukemia and Lymphoma, 2026 MCL is a rare subtype of B-cell non-Hodgkin lymphoma, accounting for approximately 5–7% of all lymphomas and showing a higher prevalence in males. MCL is characterized by the expression of CD5 and ...
Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma Swaminathan Iyer, Neha Mehta-Shah, Ranjana Advani, Nancy L. Bartlett, Jacob H. Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Onder Alpdogan, Tatyana A. Feldman, Vincent Camus, Giuseppe Gritti, Pier Luigi Zinzani, David Belada, Jiri Mayer, Ilseung Choi, June-Won Cheong, Evelyn Rustia, Keenan Fenton, Michelle Fanale, Kerry J. Savage, Steven M. Horwitz Blood Advances, 2025 In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluorodeoxyglucose PET scans after cycle 4 (PET4) and end-of-treatment–based response, and correlated with PFS per investigator and OS. PET4 response was determined by Deauville score (scores of 1-3 were considered negative [PET4-negative] and 4-5 positive [PET4-positive]) by independent review. Overall, 452 patients were randomized 1:1 to the BV-CHP (n = 226) and CHOP (n = 226) arms. Of these, 32 in the BV-CHP arm and 41 in the CHOP arm were not evaluable for PET4. In both arms, PET4-negative status was associated with improved PFS (BV-CHP: HR, 0.36; 95% CI, 0.19-0.66; CHOP: HR, 0.26; 95% CI, 0.17-0.41) and OS (BV-CHP: HR, 0.38; 95% CI, 0.18-0.78; CHOP: HR, 0.24; 95% CI, 0.14-0.41) compared with PET4-positive status. Among patients with systemic anaplastic large cell lymphoma, PET4-negative patients had improved PFS (BV-CHP: HR, 0.28; 95% CI, 0.14-0.60; CHOP: HR, 0.31; 95% CI, 0.17-0.56) and OS (BV-CHP: HR, 0.38; 95% CI, 0.16-0.94; CHOP: HR, 0.25; 95% CI, 0.12-0.55) compared with PET4-positive patients. In this exploratory analysis, PET4-negative status by Deauville score was associated with improved long-term PFS and OS in both the BV-CHP and CHOP arms. This trial was registered at www.ClinicalTrials.gov as #NCT01777152.
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial Martin Hutchings, Anna Sureda, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, Abraham Avigdor, María José Terol, Antonio Rueda Dominguez, Antonio Pinto, Alan Skarbnik, Raul Cordoba, Judit Meszaros Jørgensen, Pier Luigi Zinzani, Wilfred Leung, Alessia Bottos, Donghang Li, James Relf, Maneesh Tandon, Gila Sellam, Giuseppe Gritti Journal of Clinical Oncology, 2025 PURPOSE An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.gov identifier: NCT03533283 ) investigating efficacy and safety of glofitamab plus polatuzumab vedotin (Glofit-Pola) in patients with R/R LBCL, including HGBCL and those who received previous chimeric antigen receptor (CAR) T-cell therapy. METHODS Patients received 1,000 mg obinutuzumab on Cycle (C)1 Day (D)1 (once daily). Polatuzumab vedotin (1.8 mg/kg) was given on C1D2 and D1 of C2–6 (21-day cycles; once daily). Glofitamab was given as step-up doses in C1 (D8, 2.5 mg; D15, 10 mg) followed by 30 mg on D1 of C2–12 (21-day cycles; once daily). Polatuzumab vedotin was given for six fixed-duration cycles, and glofitamab for 12. RESULTS As of September 2, 2024, 129 patients with LBCL (HGBCL; n = 44, 34.1%), received ≥1 dose of study treatment. The median age was 67 years (range, 23-84), and 63.6% were male. Patients had received a median of 2 (range, 1-7) previous lines of treatment (previous CAR T-cell therapy, n = 28, 21.7%). The independent review committee–assessed overall response rate was 78.3% (complete response rate, 59.7%). The median progression-free survival and overall survival (OS) were 12.3 and 33.8 months, respectively (median OS follow-up time, 32.7 months). The most common adverse event (AE) was cytokine release syndrome (43.4%; grade 1-2: 41.9%; one grade 5 event). Grade 3-4 AEs occurred in 58.9% of patients; 9.3% had grade 5 AEs, and 14.7% discontinued treatment because of AEs. CONCLUSION Glofit-Pola demonstrated high efficacy and durable responses, with manageable safety, in heavily pretreated patients with R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy failure.
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage Blood Cancer Journal, 2025 Trial registration: ClinicalTrials.gov number: NCT01777152
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation Federico Lussana, Chiara F. Magnani, Stefania Galimberti, Giuseppe Gritti, Giuseppe Gaipa, Daniela Belotti, Benedetta Cabiati, Sara Napolitano, Silvia Ferrari, Alex Moretti, Chiara Buracchi, Gian Maria Borleri, Benedetta Rambaldi, Giuliana Rizzuto, Anna Grassi, Muriel Paganessi, Cristian Meli, Sarah Tettamanti, Giulia Risca, Giulia Pais, Giulio Spinozzi, Fabrizio Benedicenti, Giovanni Cazzaniga, Chiara Capelli, Elisa Gotti, Martino Introna, Josée Golay, Eugenio Montini, Adriana Balduzzi, Maria Grazia Valsecchi, Giuseppe Dastoli, Alessandro Rambaldi, Andrea Biondi Blood Cancer Journal, 2025 Non-viral engineering can ease CAR-T cell production and reduce regulatory and cost requirements. We utilized Sleeping Beauty transposon to engineer donor-derived anti-CD19.CD28.OX40.CD3zeta T cells differentiated in cytokine-induced killer (CARCIK-CD19) for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients relapsed after allogeneic hematopoietic stem cell transplantation (alloHSCT). We report the results of CARCIK-CD19 observed in 36 patients (4 children and 32 adults) treated according to the final recommended dose. Cytokine release syndrome of grade 2 or lower occurred in 15 patients, ICANS grade 2 in 1 patient, and late-onset peripheral neurotoxicity of grade 3 in 2 patients. GVHD never occurred after treatment with allogeneic CARCIK-CD19. Complete remission was achieved by 30 out of 36 patients (83.3%), with MRD negativity in 89% of responders. With a median follow-up of 2.2 years, the 1-year overall survival was 57.0%, and event-free survival was 32.0%. The median duration of response at 1 year was 38.6%. CAR-T cells expanded rapidly after infusion and remained detectable for over 2 years. Integration site analysis after infusion showed a high clonal diversity. These data demonstrated that SB-engineered CAR-T cells are safe and induce durable remission in heavily pretreated patients with BCP-ALL relapsed after alloHSCT. Trial registration: The phase 1/2 and phase II trials are registered at www.clinicaltrials.gov as NCT#03389035 and NCT#05252403.
Enhancing the diagnostic accuracy of core needle biopsy in patients with lymphoproliferative disorders by an optimized protocol Silvia Ferrari, Alessandra Weber, Paolo Marra, Paola Tebaldi, Chiara Pavoni, Anna Maria Barbui, Giuseppe Gritti, Ludovico Dulcetta, Francesco Saverio Carbone, Riccardo Muglia, Paola Anna Erba, Andrea Gianatti, Alessandro Rambaldi, Sandro Sironi Radiologia Medica, 2025 Purpose Surgical excision biopsy of lymph nodes stands as the gold standard for histological characterization of lymphoproliferative disorders (LD). However, contemporary clinical practice increasingly leans toward core needle biopsy (CNB). This study seeks to explore the factors influencing the diagnostic yield of CNB in LD. Material and Methods This unicentric retrospective study presents data from patients referred for suspicion of new or relapsing LD. All patients underwent image-guided CNB of the target lesion based on PET/CT findings. The primary endpoint was the diagnostic outcome, comparing the ability to achieve a definitive diagnosis according to international guidelines with CNB versus the necessity for subsequent excisional biopsy. Results We enrolled 478 consecutive patients undergoing CNB, categorized into two cohorts. Cohort A comprised patients who underwent CNB using 18-20G full-core Menghini needles, with a median macroscopic fragment dimension of 1 cm. Cohort B included patients who underwent CNB with 16-18G semiautomatic guillotine needles, with a median macroscopic fragment dimension of 1.5 cm. In cohort A, the rates of diagnostic and non-diagnostic (or non-sufficiently detailed) CNBs were 95 (73%) versus 35 (27%), respectively. In cohort B, these rates were 299 (86%) versus 49 (14%). Conclusion The type and size of the needle used for CNB, as well as the histologic variant of LD, emerged as factors influencing diagnostic yield and accuracy. Given the swiftness of CNB compared to surgical excision, optimizing this technique could streamline the diagnostic and therapeutic workflow for patients with suspected LD.
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia Nicola Maciocia, Malika Hoekx, Ciaran Acuna, Brandon Wade, Amy Burley, Saumya Ramanayake, Francesco Nannini, Patrycja A. Wawrzyniecka, Thaneswari Karpanasamy, Maria Schuldt, Stephanie Ng, Mathieu Ferrari, Teresa Marafioti, Giuseppe Gritti, Shimobi Onuoha, David O’Connor, Lydia Lee, Marc Mansour, Asim Khwaja, Martin Pule, Paul Maciocia Science Translational Medicine, 2025 Patients with relapsed/refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) have a dismal prognosis, highlighting the urgent need for effective therapies. Chimeric antigen receptor (CAR)–T cell approaches targeting pan–T cell antigens may be limited by T cell aplasia and fratricide, necessitating “rescue” allogeneic hematopoietic stem cell transplantation. In this study, we identify CD21, a pan–B cell marker, as a promising target for T-ALL immunotherapy. CD21 is expressed in 50% of T-ALL cases at diagnosis but in fewer than 10% of mature T cells. We observed that CAR-T cells targeting membrane-distal CD21 epitopes were ineffective, likely because of the bulky, glycosylated nature of the antigen. However, when we engineered CAR-T cells to target membrane-proximal CD21 epitopes using an antigen-binding fragment (Fab)–CAR design, we demonstrated robust activity against T-ALL cell lines, primary tumors, and patient-derived xenografts in both in vitro and in vivo models. The enhanced efficacy of this Fab-CAR design was driven by its high stability and reduced surface expression, addressing limitations of traditional CAR constructs. In addition, pharmacological inhibition of the phosphatidylinositol 3-kinase axis up-regulated CD21 expression in T-ALL, further enhancing the potency of anti-CD21 CAR-T cells in vitro and in a patient-derived xenograft in vivo model. This study establishes CD21 as a viable CAR-T target and highlights advances in CAR design for bulky antigens, as well as the potential for pharmacological strategies to augment target expression. Anti-CD21 CAR-T cells represent a promising therapeutic option for improving outcomes for patients with T-ALL.
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL Giuseppe Gritti, Silvia Ferrari, Federico Lussana, Anna Maria Barbui, Francesco Landi, Monica Rondi, Alessandro Putelli, Francesco Ballardini, Giulia Quaresmini, Muriel Paganessi, Chiara Pavoni, Arianna Ghirardi, Elisa Gotti, Chiara Capelli, Josée Golay, Martino Introna, Alessandro Rambaldi Blood Cancer Journal, 2024 First-line treatment with bendamustine-rituximab (BR) or fludarabine-cyclophosphamide-rituximab (FCR) is often used in indolent non-Hodgkin lymphoma (iNHL) and in selected cases of chronic lymphocytic leukemia (CLL) [ 1 , 2 ]. Despite the good results, combination chemotherapy using drugs with purine analog or purine analogs-like moieties (i.e. fludarabine or bendamustine) results in sustained B and T-cell depletion that can last years after treatment [ 3 , 4 ]. Indeed, it has been shown that efficient immunological recovery after chemotherapy requires multiple pathways that often evolve into a physiological age-dependent decline, resulting in a high frequency of long-term immune-deficient patients due to both dysfunctional and/or low absolute T-cell counts, especially in elderly patients [ 5 ].
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study Emmanuel Bachy, Kerry J. Savage, Huiqiang Huang, Yok-Lam Kwong, Giuseppe Gritti, Qingyuan Zhang, Anna Marina Liberati, Junning Cao, Haiyan Yang, Siguo Hao, Jianda Hu, Keshu Zhou, Mario Petrini, Filomena Russo, Huilai Zhang, Wei Sang, Jie Ji, Andrés José María Ferreri, Gandhi Laurent Damaj, Hui Liu, Wei Zhang, Xiaoyan Ke, Chiara Ghiggi, Sha Huang, Xiaotong Li, Hui Yao, Jason Paik, William Novotny, Wenxiao Zhou, Hongjie Zhu, Pier Luigi Zinzani Blood Advances, 2023
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study Elisabeth A. Lasater, Dhara N. Amin, Rajat Bannerji, Raghuveer Singh Mali, Kathy Barrett, Ryan N. Rys, Jason Oeh, Eva Lin, Tim Sterne‐Weiler, Ellen Rei Ingalla, MaryAnn Go, Shang‐Fan Yu, Maxwell M. Krem, Chris Arthur, Uwe Hahn, Anna Johnston, Vinit Karur, Nadia Khan, Paula Marlton, Tycel Phillips, Giuseppe Gritti, John F. Seymour, Monica Tani, Sam Yuen, Scott Martin, Matthew T. Chang, Christopher M. Rose, Victoria C. Pham, Andrew G. Polson, YiMeng Chang, Claudia Wever, Nathalie A. Johnson, Yanwen Jiang, Jamie Hirata, Deepak Sampath, Lisa Musick, Christopher R. Flowers, Ingrid E. Wertz American Journal of Hematology, 2023
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study Alejandro Martín García-Sancho, Monica Bellei, Miriam López-Parra, Giuseppe Gritti, María Cortés, Silvana Novelli, Carlos Panizo, Luigi Petrucci, Antonio Gutiérrez, Ivan Dlouhy, Mariana Bastos-Oreiro, Juan M. Sancho, María J. Ramírez, José M. Moraleda, Estrella Carrillo, Ana I. Jiménez-Ubieto, Isidro Jarque, Lorella Orsucci, Estefanía García-Torres, Carlos Montalbán, Anna Dodero, Reyes Arranz, Natalia De las Heras, María J. Pascual, Javier López-Jiménez, Michelle Spina, Alessandro Re, Sonia González De Villambrosia, Sabela Bobillo, Massimo Federico, Dolores Caballero Haematologica, 2022
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia Paul M. Maciocia, Patrycja A. Wawrzyniecka, Nicola C. Maciocia, Amy Burley, Thaneswari Karpanasamy, Sam Devereaux, Malika Hoekx, David O’Connor, Theresa Leon, Tanya Rapoz-D’Silva, Rachael Pocock, Sunniyat Rahman, Giuseppe Gritti, Diana C. Yánez, Susan Ross, Tessa Crompton, Owen Williams, Lydia Lee, Martin A. Pule, Marc R. Mansour Blood, 2022
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy Olga Minenkova, Daniela Santapaola, Ferdinando Maria Milazzo, Anna Maria Anastasi, Gianfranco Battistuzzi, Caterina Chiapparino, Antonio Rosi, Giuseppe Gritti, Gianmaria Borleri, Alessandro Rambaldi, Clélia Dental, Cécile Viollet, Bruno Pagano, Laura Salvini, Emanuele Marra, Laura Luberto, Antonio Rossi, Anna Riccio, Emilio Merlo Pich, Maria Gabriella Santoro, Rita De Santis Molecular Therapy, 2022
Genetic and phenotypic attributes of splenic marginal zone lymphoma Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Valeria Spina, Adalgisa Condoluci, Luisella Bonomini, Gabriela Forestieri, Ricardo Koch, Deborah Piffaretti, Katia Pini, Maria Cristina Pirosa, Micol Giulia Cittone, Alberto Arribas, Marco Lucioni, Guido Ghilardi, Wei Wu, Luca Arcaini, Maria Joao Baptista, Gabriela Bastidas, Silvia Bea, Renzo Boldorini, Alessandro Broccoli, Marco Matteo Buehler, Vincenzo Canzonieri, Luciano Cascione, Luca Ceriani, Sergio Cogliatti, Paolo Corradini, Enrico Derenzini, Liliana Devizzi, Sascha Dietrich, Angela Rita Elia, Fabio Facchetti, Gianluca Gaidano, Juan Fernando Garcia, Bernhard Gerber, Paolo Ghia, Maria Gomes da Silva, Giuseppe Gritti, Anna Guidetti, Felicitas Hitz, Giorgio Inghirami, Marco Ladetto, Armando Lopez-Guillermo, Elisa Lucchini, Antonino Maiorana, Roberto Marasca, Estella Matutes, Veronique Meignin, Michele Merli, Alden Moccia, Manuela Mollejo, Carlos Montalban, Urban Novak, David Graham Oscier, Francesco Passamonti, Francesco Piazza, Stefano Pizzolitto, Alessandro Rambaldi, Elena Sabattini, Gilles Salles, Elisa Santambrogio, Lydia Scarfò, Anastasios Stathis, Georg Stüssi, Julia T. Geyer, Gustavo Tapia, Corrado Tarella, Catherine Thieblemont, Thomas Tousseyn, Alessandra Tucci, Giorgio Vanini, Carlo Visco, Umberto Vitolo, Renata Walewska, Francesco Zaja, Thorsten Zenz, Pier Luigi Zinzani, Hossein Khiabanian, Arianna Calcinotto, Francesco Bertoni, Govind Bhagat, Elias Campo, Laurence De Leval, Stefan Dirnhofer, Stefano A. Pileri, Miguel A. Piris, Alexandra Traverse-Glehen, Alexander Tzankov, Marco Paulli, Maurilio Ponzoni, Luca Mazzucchelli, Franco Cavalli, Emanuele Zucca, Davide Rossi Blood, 2022
DeepMIF: Deep Learning Based Cell Profiling for Multispectral Immunofluorescence Images with Graphical User Interface Yeman Brhane Hagos, Ayse U Akarca, Alan Ramsay, Riccardo L Rossi, Sabine Pomplun, Alessia Moioli, Andrea Gianatti, Christopher Mcnamara, Alessandro Rambaldi, Sergio A. Quezada, David Linch, Giuseppe Gritti, Teresa Marafioti, Yinyin Yuan Lecture Notes in Computer Science Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics, 2022
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner, Carlo Calzetti, Nicola Duccio Salerno, Luigi Atripaldi, Marco Cascella, Massimo Costantini, Giovanni Dolci, Nicola Cosimo Facciolongo, Fiorentino Fraganza, Marco Massari, Vincenzo Montesarchio, Cristina Mussini, Emanuele Alberto Negri, Gerardo Botti, Claudia Cardone, Piera Gargiulo, Adriano Gravina, Clorinda Schettino, Laura Arenare, Paolo Chiodini, Ciro Gallo, Francesco Perrone, Maria Carmela Piccirillo, Clorinda Schettino, Adriano Gravina, Piera Gargiulo, Claudia Cardone, Laura Arenare, Paolo Antonio Ascierto, Maria Grazia Vitale, Claudia Trojaniello, Marco Palla, Attilio Antonio Montano Bianchi, Gerardo Botti, Gianfranco De Feo, Leonardo Miscio, Ciro Gallo, Paolo Chiodini, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Marco Froldi, Lorenzo Menicanti, Maria Teresa Cuppone, Giulia Gobbo, Chiara Baldessari, Vincenzo Valenti, Serenella Castelvecchio, Federica Poli, Francesca Giacomazzi, Rosangela Piccinni, Maria Laura Annnunziata, Andrea Biondi, Cecilia Bussolari, Manuel Mazzoleni, Andrea Giachi, Annalisa Filtz, Arianna Manini, Enrico Poletti, Federico Masserini, Francesco Conforti, Gianfranco Gaudiano, Vittoria Favero, Alice Moroni, Tommaso Viva, Fabiana Fancoli, Davide Ferrari, Dario Niro, Marco Resta, Andrea Ballotta, Marco Dei Poli, Marco Ranucci, Diego Ripamonti, Francesca Binda, Alessandra Tebaldi, Giuseppe Gritti, Luisa Pasulo, Leonardo Gaglio, Roberto Del Fabbro, Leonardo Alborghetti, Paolo Bonfanti, Nicola Squillace, Giulia Giustinetti, Paola Columpsi, Marina Cazzaniga, Serena Capici, Luca Sala, Riccardo Di Sciacca, Giacomo Mosca, Maria Rosa Pirozzi, Francesco Castelli, Maria Lorenza Muiesan, Franco Franceschini, Aldo Roccaro, Massimo Salvetti, Anna Paini, Luciano Corda, Chiara Ricci, Lina Tomasoni, Paola Nasta, Silvia Lorenzotti, Silvia Odolini, Emanuele Focà, Eugenia Quiros Roldan, Marco Metra, Stefano Magrini, Paolo Borghetti, Nicola Latronico, Simone Piva, Matteo Filippini, Gabriele Tomasi, Francesco Zuccalà, Sergio Cattaneo, Francesco Scolari, Nicola Bossini, Mario Gaggiotti, Martina Properzi, Miriam Lichtner, Cosmo Del Borgo, Raffaella Marocco, Valeria Belvisi, Tiziana Tieghi, Margherita De Masi, Paola Zuccalà, Paolo Fabietti, Angelo Vetica, Vito Sante Mercurio, Anna Carraro, Laura Fondaco, Blerta Kertusha, Ambrogio Curtolo, Emanuela Del Giudice, Riccardo Lubrano, Maria Gioconda Zotti, Antonella Puorto, Marcello Ciuffreda, Antonella Sarni, Gabriella Monteforte, Domenico Romeo, Emanuela Viola, Carla Damiani, Antonietta Barone, Barbara Mantovani, Daniela Di Sanzo, Vincenzo Gentili, Massimo Carletti, Massimo Aiuti, Andrea Gallo, Piero Giuseppe Meliante, Salvatore Martellucci, Oliviero Riggio, Vincenzo Cardinale, Lorenzo Ridola, Maria Consiglia Bragazzi, Stefania Gioia, Emiliano Valenzi, Camilla Graziosi, Niccolò Bina, Martina Fasolo, Silvano Ricci, Maria Teresa Gioacchini, Antonella Lucci, Luisella Corso, Daniela Tornese, Parni Nijhawan, Francesco Equitani, Carmine Cosentino, Marcello Palladino, Frida Leonetti, Gaetano Leto, Camillo Gnessi, Giuseppe Campagna, Roberto Cesareo, Francesca Marrocco, Giuseppe Straface, Alessandra Mecozzi, Lidia Cerbo, Valentina Isgrò, Sergio Parrocchia, Giuseppe Visconti, Giorgio Casati, Carlo Calzetti, Alarico Ariani, Lorenzo Donghi, Nicola Duccio Salerno, Evelina Tacconelli, Marco Bertoldi, Paolo Cattaneo, Lorenza Lambertenghi, Leonardo Motta, Luca Omega, Giovanni Albano, Roberto Parrella, Fiorentino Fraganza, Luigi Atripaldi, Vincenzo Montesarchio, Francesco Scarano, Annunziata De Rosa, Amalia Buglione, Sabrina Lavoretano, Gianfranco Gaglione, Mario De Marco, Vincenzo Sangiovanni, Francesco Maria Fusco, Rosaria Viglietti, Elio Manzillo, Carolina Rescigno, Raffaella Pisapia, Giulia Plamieri, Alberto Maraolo, Giosuè Calabria, Mario Catalano, Giuseppe Fiorentino, Anna Annunziata, Giorgio Polistina, Pasquale Imitazione, Mariano Mollica, Vincenzo Esposito, Maurizio D’Abraccio, Rodolfo Punzi, Vincenzo Bianco, Costanza Sbreglia, Rosa Fontana Del Vecchio, Alessandro Bordonali, Antonina Franco, Carlo Salvarani, Marco Massari, Giovanni Dolci, Pierpaolo Salsi, Matteo Fontana, Giuseppe Virzì, Ornella Calderone, Alfredo Molteni, Silvia Gennarini, Umberto Gnudi, Maria Anastasia Ricci, Giancarlo Titolo, Giulio Mensi, Pietro Vuotto, Beatrice Gasperini, Mauro Mancini, Zeno Pasquini, Paolo Spanu, Stefano Clementi, Simona Pierini, Daniela Bokor, Daniela Gori, Morena Ciofetti, Marina Caimi, Laura Bettazzi, Elisabetta Allevi, Silvia Furiani, Chiara Capitanio, Bernardino Mastropasqua, Claudio Fara, Grazia Pulitanò, Jun Sebastian Matsuno, Francesca Della Porta, Viola Dolfini, Nebiat Balei Beyene, Michela Bezzi, Mauro Novali, Pierluigi Viale, Sara Tedeschi, Renato Pascale, Raffaele Bruno, Alessandro Di Filippo, Michele Sachs, Tiberio Oggionni, Michele Di Stefano, Caterina Mengoli, Cesarina Facchini, Daniele De Nardo, Gabriele Frausini, Luciano Mucci, Silvia Tedesco, Rita Girolimetti, Elena Manfredini, Anna Maria Di Carlo, Emma Espinosa, Donatella Dennetta, Andrea Ticinesi, Tiziana Meschi, Antonio Nouvenne, Claudio Norbiato, Francesco Vitale, Marta Saracco, Mauro Codeluppi, Elisa Fronti, Patrizia Ferrante, Giorgio Amadio Nespola, Daniela Francisci, Andrea Tosti, Cristiano Matteo Carbonelli, Antonio Greco, Maria Giulia Tinti, Roberto Stellini, Camilla Appiani, Piera Reghenzi, Venerino Poletti, Claudia Ravaglia, Danilo Tacconi, Costanza Malcontenti, Pier Paolo Sainaghi, Raffaella Landi, Veronica Vassia, Eleonora Rizzi, Mattia Bellan, Antonella Rossati, Luigi Castello, Claudio Maria Mastroianni, Gianluca Russo, Fabio Toffoletto, Francesco Saverio Serino, Lucio Brollo, Elena Momesso, Maria Luisa Turati, Antonella D’arminio Monforte, Giulia Marchetti, Fabrizio Boni, Elisabetta Teopompi, Chiara Trenti, Luca Boracchia, Enrica Minelli, Matteo Fontana, Giulia Ghidoni, Anaflorina Matei, Andrea Caruso, Giuseppe Arcoleo, Gaetana Camarda, Filippo Catalano, Mario Spatafora, Donato Bettega, Massimo Andreoni, Elisabetta Teti, Loredana Sarmati, Andrea Di Lorenzo, Mariagrazia Celeste, Fabio Baratto, Jacopo Monticelli, Pietro Criveller, Andrea Antonini, Anselmo, Riccio, Maurizio Castellano, Carlo Cappelli, Federica Corvini, Barbara Zanini, Massimo Crippa, Maurizio Ronconi, Raffaella Costa, Silvia Casella, Loretta Brentana, Livio Bernardi, Andrea Frascati, Sandro Panese, Fabio Presotto, Lucio Michieletto, Cristina Bernardi, Maurizio Fusar, Vanni Agnoletti, Martina Farina, Russo, Federico Lavorini, Roberta Ginanni, Fabrizio Palmieri, Silvia Mosti, Angelo Amaglio, Alessandra Cattaneo, Silvia Cirri, Andrea Montisci, Chiara Gallazzi, Daniele Cosseta, Barabara Baronio, Lorenzo Rampa, Paolo Maggi, Vincenzo Messina, Emanuele Alberto Negri, Chiara Trenti, Maria Cecilia Sabatti, Michele Palumbo, Antonino Mazzone, Paola Faggioli, Linda Bussini, Giacomo Fornaro, Francesca Volpato, Daniele Imperiale, Emilpaolo Manno, Enrico Ferreri, Domenico Martelli, Andrea Verhovez, Silvia Giorgis, Luciana Faccio, Rachele Delli Quadri, Cristina Negro, Marcella Converso, Francesca Bosco, Silvia Amadosi, Paolo Prandini, Silvia Cocchi, Vinicio Manfrin, Veronica Del Punta, Giovanni Mazzola, Giuseppe Sportato, Micaela Romagnoli, Francesco Cristini, Francesca Facondini, Tiziana Perin, Andrea Boschi, Cristina Mussini, Marianna Meschiari, Giovanni Guaraldi, Sara Modica, Sara Moneta, Daniela Boccalatte, Clara Ricci, Valentina Marchetti, Silvia Amadasi, Gabriele Ebbreo, Michael Dalè, Paolo Tura, Damiano Rizzoni, Gianluca Edoardo Mario Boari, Silvia Bonetti, Enrico Marini, Italiani Daniele, Paolo Antonio Grossi, Nichola Walter Delfrate, Othmar Bernhart, Gilbert Spizzo, Klaus Mahlknecht, Thomas Volkl, Massimo Antonio Di Pietro, Michele Trezzi, Cecilia Monacci, Adriano Peris, Manuela Bonizzoli, Luigi Cavanna, Carlo Moroni, Elisa Maria Stroppa, Alessandra Manini, Maria Cristina Savio, Francesca Gatti, Clara Bartolaminelli, Nicola Petrosillo, Davide R. Donno, Fabrizio Taglietti, Simone Topino, Pierangelo Chinello, Vincenzo Galati, Gianpiero D’offizi, Chiara Taibi, Barbara Cimolato, Federico Moroni, Nicolas Palagano, Lorenzo Pelagatti, Cristiana Seravalle, Giancarlo Landini, Maria Amitrano, Mariangela Raimondo, Sara Mangiacapra, Annamaria Romano, Mariangela Atteno, Pierluigi Blanc, Lorenzo Roberto Suardi, Carlo Pallotto, Katia Casinelli, Ilaria Uccella, Sergio Harari, Antonella Caminati, Filippo Lipani, Giovanni Di Perri, Andrea Calcagno, Guido Calleri, Chiara Montrucchio, Anna Maria Caputo, Susanna Cozzio, Livia Delle Donne, Matteo Bassetti, Mikulska Malgorzata, Laura Ambra Nicolini, Chiara Russo, Chiara Sepulcri, Sabrina Beltramini, Federica Mina, Massimo Puoti, Anna Gandino, Thomas Langer, Federico D’amico, Marialma Berlendis, Chiara Rocchetti, Francesca Cettolo, Gabriele Fausini, Pietro Bocchi, Giorgio Cioni, Cinzia Cappi, Silvia Corcione, Francesco Giuseppe De Rosa, Silvia Scabini, Francesca Canta, Simone Mornese Pinna, Anna Pensa, Pierluigi Blanc, Lorenzo Roberto Suardi, Carlo Pallotto, Monica Rocco, Maria Teresa Cirasa, Michele Spinicci, Jessica Mencarini, Lorenzo Zammarchi, Giovanni Cenderello, Katiuscia Sciolè, Flavio Bassi, Michele Bianchi, Sillia Frigerio, Sandra Spaziani, Antonia Nucera, Giuliano Rizzardini, Maria Vittoria Cossu, Marco Antivalle, Giuseppe Carpinteri, Sebastiano Macheda, Demetrio Labate, Maurizio Bottiroli, Anacleto Romano, Elke Maria Erne, Zocchetti Cristina, Valeria Di Biase, Fabio Malberti, Giovanni Montani, Paolo Poisa, Daniela Bettini, Roberto Cauda, Arturo Ciccullo, Niccolò Riccardi, Andrea Angheben, Mauro Turrini, Raffaella Clerici, Angelo Gardellini, Luigi Liparulo, Tizana Rossini, Claudio Ucciferri, Francesco Cipollone, Jacopo Vecchiet, Andrea Nico, Lorenzo Marra, Armando Leone, Antonia Sdanganelli, Giuseppe Antonio Palmiotti, Giancarlo D’Alagni, Teresa Antonia Santantonio, Sergio Lo Caputo, Irene Bottalico, Antonio Ponticiello, Felicia Di Perna, Enrico Bernardi, Angela Beltrame, Stefania Bravi, Marco David, Paola Bernardi, Dario Galante, Maria Cristina Uccelli, Katiela Prestini, Monica Drera, Enea Zini, Alessio Peregrinelli, Laura Blanzuoli, Valentina Benedetti, Roberta Calvi, Nadia Scaglione, Gabriella Nallino, Maurizio Bonazzi, Tiziano Crespi, Tiziana Masolin, Angelo Regazzetti, Maria Chiara Cerri, Elena Maffezzini, Manuela Piazza, Claudia Papetti, Claudia De Filippi, Elena Roveda, Giuseppe Cipolla, Mariano Scozzafava, Monica Crepaldi, Sonia Henchi, Nicolò Vanoni, Alice Repossi, Monia Vezzoli, Eva Scorletti, Orietta Perugini, Simone Marino Pasini, Veronica Pacetti, Luisella Ferrari, Giovanna Attilia de Paduanis, Sara del Duca, Francesca dell’Ara, Alessandra Brocchieri, Guja Minoja, Enrico Storti, Loredana Pitagora, Isabella Costa, Fanny Delfanti, Matteo Orlandi, Ruggero Ruggeri, Lorenzoa Ruggieri, Sergio Livigni, Daniela Silengo, Walter Ageno, Luciano Pedrini, Stefania Artiol, Laura Morbidoni, Giuseppe De Donno, Viviana Ravagnani, Francesco Inglese, Pier Giorgio Scotton, Paolo Costantini, Maurizio Delucchi, Enrico Clini, Andrea Ansuini, Marco Baiocchi, Giuseppe Lain, Brianti Vincenzo, Gianni Rastelli, Andrea Doria, Andrea Vianello, Anna Maria Cattelan, Sara Bindoli, Mara Felicietti, Ciro Canetta, Alessandro Scartabellati, Silvia Accordino, Maurizio Ferrara, Livio Cocco, Fernanda Cirillo, Erminio Pace, Monica De Caro, Marielisa Alberico, Giovanni Benigni, Terenzio Damiano, Pierluigi Fusco, Angela Iuorio, Giacomo Torretta, Milena Racagni, Stefano Muttini, Girolamo Sala, Paolo Ghiringhelli, Fernando Chiumiento, Laura Baccari, Enrica Minelli, Luca Boracchia, Federica Bocchi, Francesco Benatti, Jacopo Catellani, Marina Coppola, Alberto Papi, Enrico Bosco, Mnuela Bonizzoli, Chiara Lazzeri, Nencioni Cesira, Camilla Puttini, Tiziana Carli, Leonardo Croci, Marta Corridi, Massimo Arlotti, Giulio Guerrini, Luisanna Cola, Michela Romanelli, Marina Bonifazi, Stefano Gasparini, Federico Mei, Elisabetta Cerutti, Donato Lacedonia, Armando Santoro, Giacomo Maria Guidelli, Stefano Greco, Andrea Castellan, Gessica Infantino, Laura Camici, Francesca Covani Covani Frigieri, Vittorio Pavoni, Lucia Migliori, Barbara Rossetti, Francesca Montagnini, Immacolata Mauro, Elvira Genovese, Antonio Capuozzo, Leonarda Vitiello, Emanuele Sirignano, Paolo Gnesin, Giuseppe Servillo, Alfredo Marinelli, Daniela Pasero, Sergio Babudieri, Giordano Madeddu, Andrea De Vito, Lorenzo Casadio, Melania Ranghitta, Rodolfo Passalacqua, Antonio Fioravanti, Alfredo Molteni, Ivan Gentile, Antonio Riccardo Buonomo, Riccardo Scotto, Emanuela Zappulo, Giuseppina Dell’Aquila, Angel Bianchetti, Fabio Guerini, Alfredo Vallone, Peppino Oppedisano, Dario Galante, Luigi Pusterla, Omar Giglio, Grazia Russo, Enrico Sartori, Cristina Zanardini, Pietro Gatti, Vincenzo Valiani, Guido Calleri, Stefania Piconi, Chiara Molteni, Giuseppina Dognini, Franco Cosimo, Luigi Guarneri, Fabrizio Pulvirenti, Vincenzo Mondino, Gabriella Traballi, Enrico Iemoli, Antoenlla Grisolia, Riccardo Giorgi, Gabriella Nucera, Valentina Raffaelli, Pietro Marino, Enrica Negro, Lisa Serati, Silvia Tamanini, Carmelo Iacobello, Giuseppe Strano, Lucio Boglione, Alberto Catania, Paola Gipponi, Luca Di Cato, Anna Panaccione, Giovanni Vitale, Ilaria Alice Crippa, Matteo Giacomini, Adriano Basile, Andrea Bellone, Paolo Tundo, Stefano Buzzigoli, Gerardo Palmiero, Andrea Magnaca, Matteo Silva, Massimo Ricci, Stefano Crespi, Bernadetta Pasquino, Guglielmo Consales, Damiano Bragantini, Franco Mastroianni, Gianluca Russo, Giulia Righetti, Antonio Scarafino, Michele Bitetto, Fabio Franzetti, Sandro Piga, Vito Delmonte, Sergio Carbonara, Ruggero Losappio, Christian Dejaco, Claudio Mastroianni, Gianluca Russo, Valerio Del Bono, Fabio Gilioli, Daniela Barzan, Silvia De Struppi, Antonio Carlotto, Maria Licia Guadagnin, Massimo Girardis, Elisabetta Bertellini, Francesco Dentali, Giancarlo Foresta, Alberto Baratta, Rosangela Viviani, Antonio Maria Agrati, Giovanni Battista Perego, Arturo Montineri, Rosa Manuele, Salvatore Bonfante, Donatella Aquilini, Alessandra Prozzo, Donato Santopuoli, Zaira Di Rosa, Armando Alborghetti, Paolo Peci, Nikoloz Bakhtadze, Chiara Stefania Pandini, Giovanni Casati, Najat Ashofarir, Giampaolo Casella, Walter Spagnolli, Silvana Urru, Ivan Marchesoni, Giulia Caminiti, Elena Argilloni, Elisabetta Danieli, Gianluca Ghirardi, Chiara Maria Antonioli, Alessio Lipari, Paola Zavarise, Francesco Kokaly, Enrico Polati, Leonardo Gottin, Paolo Lucernoni, Fabio De Conti, Elisabetta Marcon, Emanuele Pontali, Elisabetta Blasi Vacca, Carolina Saffioti, Alessia Zunino, Erik Roman Pognuz, Giorgio Berlot, Martino Saltori, Andrea Tedesco, Silvia Amadasi, Carlo Agostini, Maria Antonietta Di Rosolini, Francesco Marino, Guido Bellinzona, Walter Grassi, Marco Di Carlo, Guglielmo Scimonello, Sandra Nonini, Michele Mondino, Lorenzo Filippo Mantovani, Elena Tenti, Concetta Maria Gabriella Tropea, Daniela Emanuela Di Stefano, Paolo Guelfi, Lorenzo Dagna, Gianfranco Morgana, Lidia Montemurro, Domenico Girelli, Ernesto Crisafulli, Alessio Maroccia, Alessandra Maria Cemuschi, Mara Bernasconi, Ugo Zummo, Valentina Barbato, Simona Bevilacqua, Gaetano Buonfanti, Giuliana Canzanella, Giovanni De Matteis, Manuela Florio, Marilena Martino, Maria Teresa Ribecco, Fiorella Romano, Alfonso Savio, Lucia Sparavigna, Marcello Curvietto, Michele Citarella, Valeria Nava, Paola Maggioni, Marta Magni, Chiara Iommelli, Antonella Bianco, Romina Corsini, Linda Valli, Maria Paola Ruggieri, Tiziana Melica, Alessandra Ferrari, Daniela Cicognini, Mariangela Delliponti, Andrea Zuccarini, Silvia Ciani, Davide Raffaeli, Luca Donati, Stefania Cannizzo, Stefania Lui, Luca Santini, Enrica Roncaglia, Pasquale Mighali, Frederik Eisendle, Giulia Cerino, Chiara Citterio, Camilla Di Nunzio, Annalisa Mancini, Silvia Lamonica, Silvia Resimini, Giovanni Sarteschi, Chiara Pavei, Nicholas Battistini, Ospedale Erika Gazzola, Marco Miceli, Silvia Pontiggia, Veronica Lonati, Giusy Giannandrea, Claudio Sortino, Serena Ravani, Cristiano Uggeri, Genny Jocollé, Cristina Baré, Irene Baroni, Daniele De Candia, Barbara Fiorini, Katiuscia Chierico, Francesca Romeo, Roberta Bottega, Laura Boccasile, Annamaria Corsaro, Claudia Spadoni, Silvia Chiari, Giovanna Ercolino, Vanessa Dell’uomo, Sabrina Viri, Milena Minato, Lisa Gazzola, Balan Dorina, Davide Gianelli, Sonia Maspero, Maddalena Farinazzo, Paola Zanini, Antonella Sangiovanni, Antonia Del Giudice, Maria Margherita Dragonetti, Susanna Bordignon, Andrea Marco Machiavelli, Giulia Chiodelli, Micaela Spatarella, Davide Zenoni, Flavio Niccolò Beretta, Giuseppina Santilli, Rita Badagliacca, Manuela Angileri, Luciana Giannelli, Annalisa Campomori, Patrizia Maimone, Andrea Fadda, Sonia Faoro, Alessia Pisterna, Bruno Cacopardo, Andrea Marino, Alessio Pampaloni, Benedetto Maurizio Celesia, Gilda Cinnella, Daniela Labella, Rosa Roberta Caporusso, Maria Danzi, Marta Fiscon, Marina Malena, Doris Fendt, Stefano Nardi, Paolo Stobbione, Maria Laura Savi, Andrea De Monte, Alberto Scala, Nicola Lucio Liberato, Sauro Luchi, Antonella Vincenti, Luca Cabrini, Giovanni Pinelli, Lucio Brugioni, Domenico Potenza, Fabio Giuliano Numis, Giovanni Porta, Maria D’amico, Bianca Iengo, Gioacchino Angarano, Annalisa Saracino, Livio Blasi, Pasquale De Negri, Stefano Angelici, Antonella Farina, Giuseppe Pio Martino, Giuseppina Bitti, Alberto Tedeschi, Simona De Ponti, Adriana Agostinone, Giustino Parruti, Augusta Consorte, Antonella Frattari, Amelia Filippelli, Pasquale Pagliano, Alfonso Masullo, Carmine Sellitto, Massimo Reta, Nicolò Rossi, Luigi Raumer, Silvia Andreassi, Paolo Brancaleoni, Antonina Carai, Anna Maria Salerno, Franco Marinangeli, Roberta Mariani, Antonello Ciccone, Carlo Meschini, Gianluca Santoboni, Claudio Angrisani, David Micarelli, Giovanna Tarquini, Vittorio Fregoni, Carlo Alberto Volta, Antonio Cherubini, Maria Simona Del Prete, Erika Ciarrochi, Francesca Tasca, Andrea Ballarin, Andrea Bianchin, Romeo Flocco, Vincenzo Cuzzone, Maurilio Carpinteri, Pietro Gallotti, Federica Torre, Pio Zannetti, Massimo Crapis, Sergio Venturini, Massimo Barattini, Gianluca Gori, Antonio Mastroianni, Giulio De Stefano, Michele Gilio, Giuseppe Rapisarda, Leonardo Gulisano, Maria Luisa Granata, Sebastiana Saglimbene, Maria Teresa Montalto, Ilaria Grasso, Silvana De Luca, Gaetano Magro, Florinda Messina, Bruno Scapino, Paolo Abrate, Chiara Francisco, Laura Pesce, Mauro Navarra, Michele Agosti, Silvia Pagani, Martina Piluso, Aristodemo Ricioppo, Silvia Tognella, Pierangelo Rovere, Marcello Vincenzi, Leonardo Ghirardi, Daniele Generali, Marco Ingrosso, Emilia Desiderio, Raffaele Molaro, Silvio Vitiello, Alessandro Mastroianni, Luca Lancione, Tonia Celeste Paone, Alessandro Meli, Stefano Mainardi, Valentina Rastellino, Antonia Ursillo, Paola di Grigoli, Elena Bovetto, Ivana Marina Stefanetto, Francesca Mazzola, Antonio Daniele, Claudia Bisio, Pietro Delnero, Giovanni Morando, Antonella Nava, Lemut Francesco, Fabio Fiammengo, Monica Regis, Dario Roccatello, Eugenio Sabato, Marco Maria Liccardi, Cristina Bretto, Lorenzo Lutri, Enzo Castenetto, Giuseppe Roberti, Maria Francesca Guidi, Francesco Bini, Maria Crisitna Zappa, Tiziana Trequattrini, Rosario Rivitti, Rossana Vigliarolo, Angela Succu, Marianna Lilli, Mattia Serao, Giuseppina Giogré, Annamaria Ruggieri, Kristoffer Flores, Giuseppe Vairo, Roberto Satira, Anna Lingua, Rosario Spina, Emanuele Nicastri, Gaetano Maffongelli, Filippo Barreca, Sabino Scollet, Federico Franchi, Camilla Fabbri, Pietro Minuz, Andrea Dalbeni, Paolo Zanatta, Domenico Gelormini, Anna Mandelli, Feliciano Galderisi, Elena Zoia, Maria Rita Marchi, Naile De Almeida Neves, Giorgio Carbone, Emilio Di Caterino, Anna Petrone, Carlo Andrea Usai, Francesco Bandiera, Roberto Monti, Alex Hofer, Giacomo Castiglione, Chiara Angeletti, Paolo Tarsia, Lorenzo Veronese, Paola Daniela Artoni, Dora Larussa, Roberto Fumagalli, Paolo Brioschi, Alessandro Cerutti, Paola Pasquino, Fiore Gilberto, Luca Cantadori, Gabriele Tomasoni, Lina Rachele Tomasoni, Nicola Coppola, Stefano Spolveri, Costanza Pollastri, Lorenzo Fico, Tiziana Principi, Silvia Pierantozzi, Costantino Fontana, Giuseppe Lubrano, Laura Martinelli, Stefano Bravi, Paolo Navalesi, Eugenio Serra, Enrico Cogi, Andrea Manzi, Ermenegildo Furino, Nicola Dasseni, Claudio Gentilini, Elisa Benatti, Andrea Pignatti, Giuseppe Aiello, Mario Milia, Maria Grazia Covesnon, Annalisa Brianti, Claudio Francesco, Blangetti Ilaria, Fiammetta Pagnozzi, Sabrina Mietta, Alberto Rossi, Lorenzo Maroni, Vittorio Borroni, Claudio Bellintani, Camilla Sgarabotto, Giada Bizzotto, Lucio Bucci, Giovanni Spagnuolo, Moreno Agostini, Federico Carlo Caria, Filippo Testa, Raffaele De Palma, Giuseppe Murdaca, Gabriele Zanolini, Nadia Sala, Erminio Righini, Roberto Pontremoli, Gianmarco Aondio, Ferdinando Riccardi, Maria Giovanna De Cristoforo, Fausto De Michele, Angelo Storti, Roberto Perra, Silvia Deidda, Caviglia Enrica, Federico Valastro, Matteo Giorgi Pierfranceschi, Fabio De Gennaro, Anna Laura Nardecchia, Mariateresa Castellini, Giovanni Buetto, Giovanbattista Ippoliti, Domenico Sicheri, Maria Grazia Bottoli, Blanca Martinez Lopez De Arroyabe, Alessandra Versaci, Casa Di Cura Villa Giada Pallotti, Marina Civita, Michele Grio, Nicola Liuzzi, Paola Molino, Mauro Pastorelli, Alberto Ricchiardi, Ferdinando Varbella, Angela Daniela Zeme, Cinzia Sighieri, Grazia Portale, Alessandro Olivetti, Carlo Pagnoni, Greta Moschini, Sabrina Boni, Alberto Guerra, Roberta Scudellari, Sabrina Vella, Sandro Inchiostro, Ornella Piazza, Salvatore Guarino, Giorgio Aldegheri, Giovanna Napoli, Alessandro Morettini, Eleonora Caldini, Lorenzo Menicacci, Filippo Pieralli, Monica Torrini, Loredana Poggesi, Enrico Maria Visetti, Carmelo Mangano, Stefano Visconti, Pasquale Maietta, Elisa Banfi, Stefania Cartella, Bruna Venturi, Antonia Nuceri, Elena Chiesa, Enrico Pacentra, Gianluigi Panzolato, Michella Giannotti, Cristina Bianchi, Antonello Pietrangelo, Ombretta Para, Maria Serena Rutili, Roberto Russo, Maurizio Lanfranco, Elisa Scalabrino, Agostino Tafuri, Elisa Perfetti, Tosca Chiarello, Luca Cancanelli, Manuela Otero, Greta Pannella, Francesco Bellucci, Giovanna Ferrero, Carmen Vico, Maria Serafina Stillante, Giovanna D’Andrea, Filippo Amoroso, Antonio Arcidiacono, Anna Maria Bella, Agata Belsito, Ylenia Berté, Giulia Carubia, Maria Grazia Caruso, Orazio Casella, Francesco Chiereleson, Chiara Costa, Daniela De Franco, Giuseppe Germanà, Antonio Messina, Diana Musumeci, Concetta Noto, Marco Valenti, Carlo Sorrentino, Rosanna Panico, Giuseppe Schettino, Jolanda Piccoli, Antonio Pepe, Francesco De Rosa, Mario Ottaviano, Gerarda Marrazzo, Gianna Raponi, Stefania Diberardino, Simona Bausi, Alessandro Ferrari, Sara Francesca Marini, Elena Giubellino, Giorgio Innocenti, Gaspare Gugliemi, Daniela Maccari, Izabela Baciu, and Journal of Translational Medicine, 2021
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Ferdinando Luca Lorini, Lucia Gandini, Luca Novelli, Jonathan P. Morgan, Benjamin M. J. Owens, Karan J. K. Kanhai, Gordana Tonkovic Reljanovic, Marco Rizzi, Fabiano Di Marco, Alberto Mantovani, Alessandro Rambaldi Leukemia, 2021
Skip pattern approach toward the early access of innovative anticancer drugs G. Apolone, A. Ardizzoni, A. Biondi, A. Bortolami, C. Cardone, C.M. Ciniselli, P. Conte, C. Crippa, F. de Braud, M. Duca, S. Gori, G. Gritti, A. Inno, R. Luksch, F. Lussana, M. Maio, G. Pasello, F. Perrone, A. Rambaldi, G. Rossi, D. Signorelli, G. Soverini, M. Valente, P. Verderio, G. Buzzetti ESMO Open, 2021
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 Enrico Brunetta, Marco Folci, Barbara Bottazzi, Maria De Santis, Giuseppe Gritti, Alessandro Protti, Sarah N. Mapelli, Stefanos Bonovas, Daniele Piovani, Roberto Leone, Ilaria My, Veronica Zanon, Gianmarco Spata, Monica Bacci, Domenico Supino, Silvia Carnevale, Marina Sironi, Sadaf Davoudian, Clelia Peano, Francesco Landi, Fabiano Di Marco, Federico Raimondi, Andrea Gianatti, Claudio Angelini, Alessandro Rambaldi, Cecilia Garlanda, Michele Ciccarelli, Maurizio Cecconi, Alberto Mantovani Nature Immunology, 2021
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C Leo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, Ian Chau, John A. Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan Iyer, William Townsend, Reem Karmali, Harry Miao, Igor Proscurshim, Shining Wang, Yujun Wu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch Clinical Cancer Research, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- And T-cell lymphoma models Chiara Tarantelli, Martin Lange, Eugenio Gaudio, Luciano Cascione, Filippo Spriano, Ivo Kwee, Alberto J. Arribas, Andrea Rinaldi, Thibaud Jourdan, Melanie Berthold, Andrea Sturz, Carolyn Sperl, Francesco Margheriti, Lorenzo Scalise, Giuseppe Gritti, Davide Rossi, Anastasios Stathis, Ningshu Liu, Emanuele Zucca, Oliver Politz, Francesco Bertoni Blood Advances, 2020
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients Nicola S. Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M. Pelizzari, Paola Tozzi, Maurizio Bonfichi, Federica Bocchio, Livio Gargantini, Elisa De Rosa, Giuseppe D. Vighi, Lucia Prestini, Simona Sammassimo, Niccolò Frungillo, Maria C. Pasquini, Alessandra Ragazzi, Daniele Boghi, Alessia Pastore, Eraldo Lanzi, Giuseppe Gritti, Giulia Quaresmini, Simone Voltolini, Roberta Gaiardoni, Consuelo Corti, Maria C. Vilardo, Maria L. La Targia, Giacomo Berini, Massimo Magagnoli, Claudia Bacci, Dario Consonni, Alma L. Rivolta, Giuliana Muti Hematological Oncology, 2018
Italian real-life experience with brentuximab vedotin: Results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma Alessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, Benedetta Puccini, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Carmelo Carlo-Stella, Stefan Hohaus, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Angela Gravetti, Giuseppe Gritti, Annalisa Arcari, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Virginia Naso, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Sergio Storti, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani Haematologica, 2017
Italian real life experience with brentuximab vedotin: Results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani Oncotarget, 2017
Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas Sergio Cortelazzo, Corrado Tarella, Alessandro Massimo Gianni, Marco Ladetto, Anna Maria Barbui, Andrea Rossi, Giuseppe Gritti, Paolo Corradini, Massimo Di Nicola, Caterina Patti, Antonino Mulé, Manuela Zanni, Valerio Zoli, Atto Billio, Andrea Piccin, Giovanni Negri, Claudia Castellino, Francesco Di Raimondo, Andrés J.M. Ferreri, Fabio Benedetti, Giorgio La Nasa, Guido Gini, Livio Trentin, Maurizio Frezzato, Leonardo Flenghi, Simona Falorio, Marco Chilosi, Riccardo Bruna, Valentina Tabanelli, Stefano Pileri, Arianna Masciulli, Federica Delaini, Cristina Boschini, Alessandro Rambaldi Journal of Clinical Oncology, 2016